Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
107 hedge funds and large institutions have $389M invested in Progenics Pharmaceuticals Inc in 2015 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 37 increasing their positions, 31 reducing their positions, and 13 closing their positions.
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
43% more call options, than puts
Call options by funds: $5.9M | Put options by funds: $4.14M
19% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 31
7% more funds holding
Funds holding: 100 → 107 (+7)
16% less capital invested
Capital invested by funds: $466M → $389M (-$76.4M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$7.22M |
| 2 |
State Street
Boston,
Massachusetts
|
+$6.09M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$3.5M |
| 4 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
+$1.44M |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$1.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$3.14M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$1.6M |
| 3 |
Renaissance Technologies
New York
|
-$1.59M |
| 4 |
FM
Forward Management
San Francisco,
California
|
-$1.03M |
| 5 |
RFC
Russell Frank Company
Seattle,
Washington
|
-$1.01M |
PGNX Hedge Fund Activity: Q1 2015 in Review
107 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q1 2015, worth a combined $389M — down 16% from $466M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new PGNX positions and 13 closed out — a net gain of 7 holders — while 37 added to existing stakes and 31 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $7.22M. The largest seller was Oxford Asset Management, cutting an estimated $3.14M.
- 107 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q1 2015, up from 100 in Q4 2014.
- Funds reported $389M of Progenics Pharmaceuticals Inc stock for Q1 2015, down 16% quarter-over-quarter.
- 20 funds opened new Progenics Pharmaceuticals Inc positions in Q1 2015 and 13 closed out, a net change of +7 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q1 2015 was Armistice Capital, an estimated $7.22M added.
- The largest Progenics Pharmaceuticals Inc seller in Q1 2015 was Oxford Asset Management, an estimated $3.14M sold.
Based on aggregated 13F filings for Q1 2015.